Focal adhesion kinase inhibition synergizes with nab-paclitaxel to target pancreatic ductal adenocarcinoma

被引：0
|
作者：
T. Y. S. Le Large
M. F. Bijlsma
B. El Hassouni
G. Mantini
T. Lagerweij
A. A. Henneman
N. Funel
B. Kok
T. V. Pham
R. de Haas
L. Morelli
J. C. Knol
S. R. Piersma
G. Kazemier
H. W. M. van Laarhoven
E. Giovannetti
C. R. Jimenez
机构：
[1] VU University Amsterdam,Department of Surgery, Cancer Center Amsterdam, Amsterdam University Medical Centers
[2] VU University,Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Centers
[3] University of Amsterdam,Laboratory for Experimental Oncology and Radiobiology, Cancer Center Amsterdam, Amsterdam University Medical Center
[4] VU University,OncoProteomics Laboratory, Department of Medical Oncology, Cancer, Cancer Center Amsterdam, Amsterdam University Medical Centers
[5] Oncode Institute,Cancer Pharmacology Lab, AIRC
[6] Fondazione Pisana per la Scienza,Start
[7] VU University Amsterdam,Up
[8] Azienda Ospedaliero-Universitaria Pisana,Department of Neurosurgery, Cancer Center Amsterdam, Amsterdam University Medical Centers
[9] University of Amsterdam,Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Center
来源：
Journal of Experimental & Clinical Cancer Research | / 40卷
关键词：
Pancreatic cancer; Therapy; FAK; EPHA2; MET; Phosphoproteomics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] The absence of class III β-tubulin is predictive of a favorable response to nab-paclitaxel and gemcitabine in patients with unresectable pancreatic ductal adenocarcinoma
    Kato, Akihisa
    Naiki-Ito, Aya
    Naitoh, Itaru
    Hayashi, Kazuki
    Nakazawa, Takahiro
    Shimizu, Shuya
    Nishi, Yuji
    Okumura, Fumihiro
    Inoue, Tadahisa
    Takada, Hiroki
    Kondo, Hiromu
    Yoshida, Michihiro
    Takahashi, Satoru
    Joh, Takashi
    HUMAN PATHOLOGY, 2018, 74 : 92 - 98
  • [32] Adjuvant nab-paclitaxel plus gemcitabine versus gemcitabine in resected pancreatic ductal adenocarcinoma: A Chinese single institution.
    Yin, Zhuzeng
    Liu, Rong
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [33] Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma
    Klein-Brill, Avital
    Amar-Farkash, Shlomit
    Lawrence, Gabriella
    Collisson, Eric A.
    Aran, Dvir
    JAMA NETWORK OPEN, 2022, 5 (06) : E2216199
  • [34] Relacorilant (RELA) with nab-paclitaxel (NP): Safety and activity in patients with pancreatic ductal adenocarcinoma (PDAC) and ovarian cancer (OvCA).
    Munster, Pamela N.
    Sachdev, Jasgit C.
    Fleming, Gini F.
    Borazanci, Erkut Hasan
    Grabowsky, Jennifer A.
    Sharma, Manish
    Custodio, Joseph
    Greenstein, Andrew
    Lu, Lawrence
    Nguyen, Dat
    Shepherd, Stacie Peacock
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [35] Survival outcomes based on sequence of therapy using FOLFIRINOX and nab-paclitaxel plus gemcitabine in metastatic pancreatic ductal adenocarcinoma
    Baron, Kelsey
    Nevala-Plagemann, Christopher Duane
    Moser, Justin
    Haaland, Benjamin
    Wang, Xuechen
    Garrido-Laguna, Ignacio
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [36] The relationship between dose to skeletal muscle area ratio and gemcitabine nab-paclitaxel toxicity in pancreatic ductal adenocarcinoma.
    Wong, Rachel
    Freckelton, Julia
    Croagh, Daniel
    Holt, Darcy Quinn
    Fox, Adrian
    Lee, Margaret
    Moore, Gregory Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [37] Treatment Outcome of Nab-paclitaxel Plus Gemcitabine for Leptomeningeal Carcinomatosis from Pancreatic Ductal Adenocarcinoma: An Autopsy Case Report
    Iwatsuka, Kunio
    Kikuta, Daiichiro
    Shibuya, Hitoshi
    Ogawa, Masahiro
    Gotoda, Takuji
    Moriyama, Mitsuhiko
    Nakagawara, Hiroshi
    Hemmi, Akihiro
    Yamao, Kenji
    INTERNAL MEDICINE, 2021, 60 (23) : 3743 - 3748
  • [38] Efficacy of SBP-101 With or Without Gemcitabine and/or Nab-paclitaxel in a Murine Xenograft Model of Human Pancreatic Ductal Adenocarcinoma
    Shah, A.
    Gagnon, S.
    de Marval, P. Milani
    Kiorpes, A.
    Cullen, M.
    PANCREAS, 2015, 44 (08) : 1413 - 1414
  • [39] Durable Response and Good Tolerance to the Triple Combination of Toripalimab, Gemcitabine, and Nab-Paclitaxel in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma
    Shui, Lin
    Cheng, Ke
    Li, Xiaofen
    Shui, Pixian
    Li, Shuangshuang
    Peng, Yang
    Li, Jian
    Guo, Fengzhu
    Yi, Cheng
    Cao, Dan
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [40] Survival Outcomes Based on Sequence of Therapy Using FOLFIRINOX and Nab-Paclitaxel plus Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma
    Baron, Margaret Kelsey
    Wang, Xuechen
    Nevala-Plagemann, Christopher
    Moser, Justin C.
    Haaland, Benjamin
    Garrido-Laguna, Ignacio
    PANCREAS, 2021, 50 (06) : 796 - 802
12345